Obesity, defined as an excessive accumulation of fat tissue, is increasingly recognized not only as a chronic health issue but also as a significant factor affecting various skin diseases, including psoriasis. Recent discussions among experts in endocrinology and dermatology highlight the complex interplay between obesity and skin conditions, emphasizing the inflammatory processes that may link these two health challenges.
On February 24, 2026, experts from the German Dermatological Society (DDG) and the German Association of Dermatologists (BVDD) will convene for an online press conference to explore the implications of obesity on skin diseases. This event marks the lead-up to the DERMATOLOGIE kompakt + praxisnah conference scheduled for February 26-28, 2026, in Leipzig.
Approximately one-quarter of adults in Germany are classified as obese, defined by a Body Mass Index (BMI) of 30 kg/m² or higher. This figure includes 23% of men and 24% of women. Obesity poses a considerable challenge due to its association with numerous comorbid conditions, such as type 2 diabetes and cardiovascular diseases, significantly impacting patient care and the healthcare system.
Link Between Obesity and Skin Diseases
According to Professor Matthias Blüher from the Helmholtz Institute for Metabolism, Obesity, and Vascular Research (HI-MAG), there is a heightened risk of developing comorbidities like metabolic syndrome in patients with chronic inflammatory conditions such as psoriasis. The metabolic syndrome encompasses obesity (specifically visceral fat), hypertension, dyslipidemia, and insulin resistance, which can also act as a risk factor for the onset of psoriasis.
“The link between metabolic disorders like obesity and skin conditions such as psoriasis may primarily involve inflammatory responses,” notes Blüher, who leads the Adult Obesity Clinic at Leipzig University Medical Center and teaches Clinical Obesity Research.
Mechanisms of Inflammation and Metabolism
The precise mechanisms that connect obesity with an increased risk of immune-mediated skin disorders remain to be fully understood. Research suggests that excess adipose tissue may trigger pro-inflammatory mechanisms, influencing the development of skin diseases. White adipose tissue plays a crucial role, responsible for thermoregulation, energy storage, and the secretion of regulatory peptides known as adipokines.
Adipokines, such as leptin, adiponectin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and plasminogen activator inhibitor-1 (PAI-1), have been identified as key determinants of obesity-related inflammation. Elevated serum leptin levels in individuals with obesity may help explain the connection between obesity and psoriasis. Similar relationships may exist between obesity and other inflammatory skin conditions like hidradenitis suppurativa and atopic dermatitis.
Weight Loss and Treatment Outcomes
Addressing chronic inflammatory skin conditions in individuals with significant obesity raises critical questions about how excess weight and associated inflammatory processes affect treatment success. While reducing weight could potentially enhance treatment efficacy, experts caution that substantial weight loss is often challenging for individuals with severe obesity.
Blüher emphasizes the importance of conservative obesity treatments, including dietary adjustments, physical activity, and behavioral therapy, which typically result in moderate weight loss of 3-5% of initial body weight. However, he also notes that modern pharmacological interventions are becoming vital for achieving sustained weight loss. The advent of incretin mimetics, commonly referred to as “weight loss injections,” represents a significant advancement in obesity treatment.
These medications, including GLP-1 and GIP receptor agonists, mimic the action of gut hormones, promoting insulin secretion, inhibiting glucagon release, slowing gastric emptying, and reducing appetite. Patients can experience significant weight loss of over 20%. Despite the chronic nature of obesity, these pharmacological developments are seen as milestones in treatment, though It’s essential to recognize that weight loss may not be permanent if therapy is discontinued.
Biologics and Weight Loss Synergy
For patients undergoing anti-inflammatory biologic therapy for psoriasis, concurrent weight loss can enhance the treatment’s effectiveness. “Coordination between dermatology and endocrinology specialists is crucial, but it must be tailored to each patient,” says Blüher, noting that We find potential side effects and limited knowledge about long-term consequences.
Common side effects of these weight loss injections include gastrointestinal issues such as nausea, reduced appetite, early satiety, and vomiting. Interestingly, emerging studies suggest that incretin mimetics like semaglutide and tirzepatide may also influence addiction mechanisms, indicating a broader impact on health beyond weight management.
As the medical community continues to unravel the intricate relationships between obesity and skin diseases, the upcoming discussions at the KoPra conference will be crucial for developing integrated treatment approaches for affected patients.
For more information about the conference and participation, please refer to the official program.
This article is intended for informational purposes only and does not constitute medical advice.
